Device Area
Regulatory, IDE, and quality support for transcatheter structural heart, cardiac rhythm management, lead management, and cardiovascular software devices.
This device area covers transcatheter structural heart devices — valve repair and replacement systems, including tricuspid and mitral platforms — cardiac rhythm management devices, lead management and extraction systems, and cardiovascular software as a medical device, including ECG analysis, arrhythmia detection, and imaging-derived measurement tools.
Cardiovascular devices are generally reviewed within CDRH's cardiovascular device review structure, and a few review themes come up repeatedly: a refined target population rather than a broad cardiovascular indication, clearly defined device success criteria set before the study starts, and a direct comparison against the transcatheter and surgical alternatives already available to that patient population. For first-in-human and early implantable programs, FDA also looks closely at whether non-U.S. cohort data is representative of the U.S. population and standard of care the device will actually be used in. Early Feasibility Study (EFS) is the usual entry point for a genuinely novel implantable mechanism, letting the sponsor refine the device and protocol with a small patient cohort before a larger pivotal study.
The Clinical & IDE practice leads cardiovascular and cardiac rhythm programs, since most of the work in this area runs through IDE strategy, Breakthrough Device requests, and clinical study design. The Regulatory Submissions practice handles Pre-Submission meetings, Breakthrough Device Designation requests, and PMA preparation alongside it. The Quality & Compliance practice covers design controls and clinical-quality oversight for the device and the study, and the Digital Health & Cybersecurity practice is brought in whenever the device includes connected software, such as remote monitoring or algorithm-based arrhythmia detection.
Practice Director, Clinical & IDE (Cardiovascular lead). Your practice director is named in the proposal and statement of work.
Common Questions
EFS is typically the better entry point for a genuinely novel device mechanism, small initial patient population, and an iterative design that may change based on early clinical experience. A traditional IDE fits a more settled design where the clinical question is confirmatory rather than exploratory. The choice is usually set during Pre-Submission discussion with FDA, informed by how much design uncertainty remains.
It can contribute, but FDA evaluates whether the study population, standard of care, and follow-up protocol are comparable to the intended U.S. population and practice setting — and whether the device version studied matches what will be used in the U.S. study. Non-U.S. data is a component of the IDE package, not typically a substitute for U.S. clinical evidence on its own.
Criterion 1 requires the device to treat or diagnose a life-threatening or irreversibly debilitating disease or condition. For cardiovascular devices this is usually straightforward to establish, but the request still needs to tie the specific device's intended use directly to that condition — a generic statement about cardiovascular disease severity is not enough on its own.
A non-U.S. manufacturer needs a U.S. Sponsor of Record under 21 CFR Part 812 — an entity that takes on the full set of sponsor obligations, including monitoring, reporting, and direct accountability to FDA — since FDA requires a U.S.-based sponsor contact for an IDE study run in the United States.
Get Started
30 minutes to assess your device, your pathway, and your IDE or submission strategy.